Filing Flows › Ensysce Biosciences (ENSC) › Q4 2025
Ensysce Biosciences (ENSC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Ensysce Biosciences (ENSC) reported revenue of $1.9M for the fourth quarter 2025 (Q4 2025), +44% from a year earlier and +282% from the quarter before. Operating margin was -147.8%, net loss $2.8M (147.0% of revenue).
Ensysce Biosciences, Q4 2025: revenue $1.9M (+44% year over year), operating margin -147.8%, net loss $2.8M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | +282% | +44% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $1.9M in Q4 2025, up 44% year over year and up 282% from the previous quarter.
Operating costs exceeded revenue by $2.8M, an operating margin of -147.8%. Total costs fell 4% while revenue rose 44%. The quarter ended with a net loss of $2.8M, narrower than the previous quarter's $3.7M loss.
Operating cash flow was −$1.5M. Non-cash charges added back $7K of depreciation and $24K of share-based compensation. Working capital and other items added $1.2M.
Questions
What was Ensysce Biosciences' revenue in the fourth quarter 2025?
Ensysce Biosciences (ENSC) reported revenue of $1.9M for the fourth quarter 2025 (Q4 2025), +44% from a year earlier and +282% from the quarter before.
Was Ensysce Biosciences profitable in the fourth quarter 2025?
Operating loss was $2.8M (-147.8% of revenue) and net loss $2.8M.